Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil
- PMID: 16531242
- DOI: 10.1016/j.str.2005.11.024
Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil
Abstract
Rho-kinase is a key regulator of cytoskeletal events and a promising drug target in the treatment of vascular diseases and neurological disorders. Unlike other protein kinases, Rho-kinase requires both N- and C-terminal extension segments outside the kinase domain for activity, although the details of this requirement have been elusive. The crystal structure of an active Rho-kinase fragment containing the kinase domain and both the extensions revealed a head-to-head homodimer through the N-terminal extension forming a helix bundle that structurally integrates the C-terminal extension. This structural organization enables binding of the C-terminal hydrophobic motif to the N-terminal lobe, which defines the correct disposition of helix alphaC that is important for the catalytic activity. The bound inhibitor fasudil significantly alters the conformation and, consequently, the mode of interaction with the catalytic cleft that contains local structural changes. Thus, both kinase and drug conformational pliability and stability confer selectivity.
Similar articles
-
The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.J Biol Chem. 2006 Jan 6;281(1):260-8. doi: 10.1074/jbc.M508847200. Epub 2005 Oct 24. J Biol Chem. 2006. PMID: 16249185
-
A molecular mechanism of P-loop pliability of Rho-kinase investigated by molecular dynamic simulation.J Comput Aided Mol Des. 2008 Nov;22(11):789-97. doi: 10.1007/s10822-008-9214-7. Epub 2008 Apr 15. J Comput Aided Mol Des. 2008. PMID: 18415022
-
Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil.J Enzyme Inhib Med Chem. 2003 Apr;18(2):127-38. doi: 10.1080/1475636031000093561. J Enzyme Inhib Med Chem. 2003. PMID: 12943196
-
Development of specific Rho-kinase inhibitors and their clinical application.Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52. doi: 10.1016/j.bbapap.2005.06.015. Epub 2005 Sep 12. Biochim Biophys Acta. 2005. PMID: 16213195 Review.
-
[Rho-kinase inhibitor].Nihon Rinsho. 2004 Feb;62 Suppl 2:571-4. Nihon Rinsho. 2004. PMID: 15035192 Review. Japanese. No abstract available.
Cited by
-
Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers?J Comput Aided Mol Des. 2007 Aug;21(8):421-35. doi: 10.1007/s10822-007-9126-y. Epub 2007 Jul 24. J Comput Aided Mol Des. 2007. PMID: 17646926
-
A molecular ruler regulates cytoskeletal remodelling by the Rho kinases.Nat Commun. 2015 Dec 1;6:10029. doi: 10.1038/ncomms10029. Nat Commun. 2015. PMID: 26620183 Free PMC article.
-
Immunobiological factors aggravating the fatty infiltration on tendons and muscles in rotator cuff lesions.Mol Cell Biochem. 2016 Jun;417(1-2):17-33. doi: 10.1007/s11010-016-2710-5. Epub 2016 May 9. Mol Cell Biochem. 2016. PMID: 27160936 Review.
-
Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.J Comput Aided Mol Des. 2012 Feb;26(2):249-66. doi: 10.1007/s10822-011-9509-y. Epub 2011 Dec 14. J Comput Aided Mol Des. 2012. PMID: 22167443
-
Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.J Med Chem. 2008 Nov 13;51(21):6642-5. doi: 10.1021/jm800986w. Epub 2008 Oct 4. J Med Chem. 2008. PMID: 18834107 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
